Glen Wakeman is a well-known business executive, investor, writer, entrepreneur and professional mentor. He enjoys seeing new ideas developed into reality and is an expert at making that happen. He has lived in six countries and conducted business in 32 nations over a 21-year career. He spent the bulk of the last 21 years working with GE Capital and Doral Financial Corporation. Wakeman has assisted companies with corporate startups, mergers, acquisitions, downsizings, targeted growth and new market entry projects.
Wakeman is now the Chief Executive Officer and Co-Founder of Launchpad Holdings. Launchpad Holdings was founded in 2015 and is a company dedicated to helping new entrepreneurs develop their ideas into an effective business strategy. They offer a completely automated software package that organizes new business concepts into a workable plan. Launchpad has a vast network of investment providers and financial advisers to offer clients the best support possible when they are starting their new business.
Over the last 20 years, Wakeman has obtained a significant amount of recognition as an international business leader. He spent 15 years working and living in Europe, Asia and South America (SlideShare). Wakeman has spent his career with some of the most prestigious financial companies in the world. The wisdom and experiences he has accumulated are immeasurable. His greatest pleasure in life is sharing his knowledge with other people who are eager for success. Mentoring future business leaders in achieving their goals is what his career is all about.
As a mentor to executives around the globe, Glen Wakeman strives to share his knowledge and insights with professionals that are eager to learn. He writes a well-respected blog about all things related to business and financial topics. His blog is is a fantastic resource for information. He often blogs about global affairs, emerging markets, business strategies, fiscal matters and much more. His website is a great place to visit to learn more about business and this highly accomplished man.
Amicus Therapeutics is highly passionate about its work. It is a global company in the field of biotechnology. This company is into advanced therapies for treating rare as well as orphan diseases. The company has a highly robust development pipeline that includes treatments for several genetic diseases in humans.
Migalastat is considered by Amicus Therapeutics as its lead product candidate (MarketWatch). This can be considered as personalized medicine. It is in the last stages of its development. This will be used for treating individuals who are suffering from Fabry disease. This would require genetic diagnosis. Another product candidate is SD-101. Even this is in its last stages of development. This will be the first therapy to be marketed. It can be used for the genetic connective tissue disorder known as Epidermolysis Bullosa (EB). Amicus Therapeutics is making use of its biologics along with the Chaperone-Advanced Replacement Therapy platform technologies. These are being used for developing several enzyme replacement therapy products. These can be used for Fabry disease, besides Pompe disease, as well as several other Lysosomal Storage Disorders.
The lead biologics program of Amicus Therapeutics is ATB200/AT2221. This is a Pompe disease ERT. It is to be administered along with a pharmacological chaperone.
Amicus Therapeutics offers three clinical programs. In addition, they can leverage their biologics capabilities along with platform technologies that can help in expanding their pipeline.
The biologics capabilities of Amicus Therapeutics helps to provide a unique tool that can be used for developing Enzyme Replacement Therapy products that can be used for LSDs. Presently, Amicus Therapeutics has novel ERTs already that can be used for Fabry as well as Pompe disease. Now the technology platforms can be used for creating future opportunities that can lead to novel ERT being developed for other LSDs.
Currently, Amicus Therapeutics is researching a potential protein replacement therapy. This will be used in preclinical studies for the CDKL5 deficiency. Any kind of genetic mutations on this CDKL5 gene can lead to CDKL5 protein deficiency. This disorder manifests itself as persistent seizures. These begin in infancy itself. It can lead to a severe impairment that can take place in neurological development.
More here : https://www.crunchbase.com/organization/amicus-therapeutics
In the business world there are a variety of ways for people to climb the corporate ladder. One of the ways that people use to reach higher levels is by producing great results. In any business sector, it is hard to ignore success.
When people work hard and produce outstanding results, other people notice. This is usually a proven way to move up the corporate ladder. In the investment sector, there are things that make the sector vastly different than many other business sectors.
One of the things that makes the investment sector unique is that the sector is a result based sector. People who can produce numbers can move high within companies. There are many people who have moved into executive positions based on their performance and track record.
A powerful reason many people are able to move up in the investment sector is that numbers are easy to see and determine in the investment sector. Anyone can find out the top investment sales people or the top investment companies. The numbers are accessible to almost anyone.
A way that many people have become executives in the investment sector is by going the investment manager or sales route. Both of these routes give professionals the opportunity to demonstrate their capabilities. In addition, all levels of investment companies can see the professionals.
This makes the chance of the professionals being promoted much greater. There is a great amount of competition in the investment industry. The numbers that are produced from the competition is a measure that has been used to evaluate talent for many years.
An executive who has shown that great performance pays off with promotions and honors is Brad Reifler. The current CEO of a successful investment company, Brad Reifler is an investment professional who specializes in making investment selections for investors.
The great success that Brad Reifler has produced and continues to produce regarding investment selections has been a major reason behind his rapid rise in the investment industry.
According to Bloomberg, Brad Reifler has been able to take full advantage of the opportunities presented to him. He uses his ability to make great investment selections to help him catapult the company he runs to higher levels in the investment industry.
Learn more about Brad Reifler: https://finance.yahoo.com/news/brad-reifler-forefront-capital-want-165445401.html